Magnetization transfer ratio in gray matter: A potential surrogate marker for progression in early primary progressive multiple sclerosis

Archives of Neurology

Volumn 65, Issue 11, 2008, Pages 1454-1459

  Khaleeli, Zhaleh ^a   Altmann, Daniel R ^a,b   Cercignani, Mara ^a   Ciccarelli, Olga ^a   Miller, David H ^a   Thompson, Alan J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRAIN ATROPHY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; EXPANDED DISABILITY STATUS SCALE; FEMALE; GRAY MATTER; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; UNITED KINGDOM;

ADULT; AGED; ATROPHY; BRAIN; DIAGNOSIS, DIFFERENTIAL; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PERIAQUEDUCTAL GRAY; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 55949093505     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.65.11.1454     Document Type: Article

References (34)

1. Tremlett H, Paty D, Devonshire V. The natural history of primary progressive MS in British Columbia, Canada. Neurology. 2005;65(12):1919-1923.
2. Wolinsky JS, Narayana PA, O'Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007;61(1):14-24.
3. McFarland HF, Barkhof F, Antel J, Miller DH. The role of MRI as a surrogate outcome measure in multiple sclerosis. Mult Scler. 2002;8(1):40-51.
4. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989;8(4):431-440.
5. Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol. 2004;56(3):407-415.
6. Tofts P. Quantitative MRI of the Brain. Chichester, England: John Wiley & Sons; 2004.
7. Ramió-Torrentà L, Sastre-Garriga J, Ingle GT, et al. Abnormalities in normal appearing tissues in early primary progressive multiple sclerosis and their relation to disability: a tissue specific magnetisation transfer study. J Neurol Neurosurg Psychiatry. 2006;77(1):40-45.
8. Sastre-Garriga J, Ingle GT, Chard DT, Ramió-Torrentà L, Miller DH, Thompson AJ. Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis. Neuroimage. 2004;22(1):353-359.
9. Khaleeli Z, Cercignani M, Audoin B, Ciccarelli O, Miller DH, Thompson AJ. Localized grey matter damage in early primary progressive multiple sclerosis contributes to disability. Neuroimage. 2007;37(1):253-261.
10. Khaleeli Z, Sastre-Garriga J, Ciccarelli O, Miller DH, Thompson AJ. Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over 1 year in early primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2007;78(10):1076-1082.
11. Thompson AJ, Montalban X, Barkhof F, et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol. 2000;47(6):831-835.
12. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444- 1452.
13. Lechner-Scott J, Kappos L, Hofman M, et al. Can the Expanded Disability Status Scale be assessed by telephone? Mult Scler. 2003;9(2):154-159.
14. Geurts JJ, Bo L, Pouwels PJ, Castelijns JA, Polman CH, Barkhof F. Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol. 2005;26(3):572-577.
15. Sastre-Garriga J, Ingle GT, Chard DT, et al. Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study. Brain. 2005;128(pt 6):1454 -1460.
16. Valsasina P, Benedetti B, Rovaris M, Sormani MP, Comi G, Filippi M. Evidence for progressive gray matter loss in patients with relapsing-remitting MS. Neurology. 2005;65(7):1126-1128.
17. Horakova D, Cox JL, Havrdova E, et al. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study. J Neurol Neurosurg Psychiatry. 2008;79(4):407-414.
18. Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol. 2001;50(3):389-400.
19. Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology. 2007;68(22)(suppl 3):S22-S31.
20. Brownell B, Hughes JT. The distribution of plaques in the cerebrum in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1962;25:315-320.
21. Stankiewicz J, Panter SS, Neema M, Arora A, Batt CE, Bakshi R. Iron in chronic brain disorders: imaging and neurotherapeutic implications. Neurotherapeutics. 2007;4(3):371-386.
22. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005;128(pt 11):2705-2712.
23. Pirko I, Lucchinetti CF, Sriram S, Bakshi R. Gray matter involvement in multiple sclerosis. Neurology. 2007;68(9):634-642.
24. Patrikios P, Stadelmann C, Kutzelnigg A, et al. Remyelination is extensive in a subset of multiple sclerosis patients [published correction appears in Brain. 2007;130(pt 3):879]. Brain. 2006;129(pt 12):3165-3172.
25. Agosta F, Rovaris M, Pagani E, Sormani MP, Comi G, Filippi M. Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain. 2006;129(pt 10):2620-2627.
26. Zhou LQ, Zhu YM, Grimaud J, Hermier M, Rovaris M, Filippi M. A new method for analyzing histograms of brain magnetization transfer ratios: comparison with existing techniques. AJNR Am J Neuroradiol. 2004;25(7):1234-1241.
27. Filippi M, Rocca MA. Magnetization transfer magnetic resonance imaging of the brain, spinal cord, and optic nerve. Neurotherapeutics. 2007;4(3):401-413.
28. Tofts PS, Steens SC, Cercignani M, et al. Sources of variation in multi-centre brain MTR histogram studies: body-coil transmission eliminates inter-centre differences. MAGMA. 2006;19(4):209-222.
29. Rovaris M, Agosta F, Sormani MP, et al. Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study. Brain. 2003;126(pt 10):2323-2332.
30. Fazekas F, Soelberg-Sorensen P, Comi G, Filippi M. MRI to monitor treatment efficacy in multiple sclerosis. J Neuroimaging. 2007;17(suppl 1):50S-55S.
31. Simon JH. Brain atrophy in multiple sclerosis: what we know and would like to know. Mult Scler. 2006;12(6):679-687.
32. Sastre-Garriga J, Ingle GT, Rovaris M, et al. Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data. Neurology. 2005;65(4):633-635.
33. Ebers GC. Natural history of primary progressive multiple sclerosis. Mult Scler. 2004;10(suppl 1):S8-S13.
34. Bieniek M, Altmann DR, Davies GR, et al. Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2006;77(9):1036-1039.